Hans Henrik Lervang

Publikationer pr. år

Fingeraftryk

Dyk ned i forskningsemnerne, hvor Hans Henrik Lervang er aktive. Disse emneetiketter kommer fra denne persons arbejder. Sammen danner de et unikt fingerprint.

1 Lignende profiler

4 Tidsskriftartikel
1 Konferenceabstrakt til konference

Liraglutide treatment reduced interleukin 6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy
Brock, C., Hansen, C. S., Karmisholt, J., Møller, H. J., Juhl, A., Farmer, A. D., Drewes, A. M., Riahi, S., Lervang, H. H., Jakobsen, P. E. & Brock, B., nov. 2019, I: British Journal of Clinical Pharmacology. 85, 11, s. 2512-2523 12 s.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
60 Citationer (Scopus)
Cardiovascular and other outcomes postintervention with insulin glargine and omega-3 fatty acids (ORIGINALE)
Hildebrandt, P., Mann, J., Ahmad, S., Parnas, A., Rodriguez, C., West, A., Huynh, T., Richard, C., Chen, L., Chen, M., Gong, Y., Han, X., Li, X., Li, Y., Liu, Z., Lu, J., Wang, C., Wang, X., Wu, H. & Perez, M. & 75 flere, Andersen, H., Christensen, P., Christiansen, M., Clemmensen, K., Gislason, G., Hansen, K., Jeppesen, J., Krarup, T., Lervang, H., Lund, S., Molvig, J., Perrild, H., Roenne, H., Seibaek, M., Soendergaard, H., Sorensen, L., Torp-Pedersen, C., Tuxen, C., Urhammer, S., Vadstrup, E., Bieler, T., Klein, C., Klein, D., Witt, K., Szabo, A., Mirza, A., Lee, J., Martinez, G., Larsen, I., Gomez, M., Mathiesen, U., Nilsson, L., Rosengren, A., Sari, R., Ali, A., Martin, M. E., Andersen, I., Jeppesen, E., Shah, K., Eriksen, S., Meyer, A., Beck, A., Andersen, K., Schmidt, N., Smith, B., He, Y., Huang, C., Ma, Y., Wang, H., Martinez, M., Bulow, M., Jansen, S., Johansen, A., Jorgensen, A., Kruse, A., Lund, K., Lundgaard, M., Madsen, J., Nedergaard, A., Nielsen, S., Olsen, A., Paulsen, S., Herold, M., Li, L., Andresen, B., Hansen, H., Iversen, E., Rodriguez, C., Andersson, C., Johansson, K., Johansson, S., Olofsson, M., Baker, M., Thomas, J. & ORIGIN Trial Investigators, 1 maj 2016, I: Diabetes Care. 39, 5, s. 709-716 8 s.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
52 Citationer (Scopus)
Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention)
The ORIGIN Trial Investigators Hamilton, Ontario, Canada, 1 jan. 2008, I: American Heart Journal. 155, 1, s. 26.e1-26.e13
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
152 Citationer (Scopus)
Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs
Thisted, H., Johnsen, S. P., Monster, T., Olsen, M., McLaughlin, J., Sørensen, H. T., Lervang, H. H. & Rungby, J., 2007.
Publikation: Konferencebidrag › Konferenceabstrakt til konference › Forskning › peer review
Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs
Johnsen, S. P., Monster, T., Olsen, M. L., Thisted, H., McLaughlin, J., Sørensen, H. T., Lervang, H. H. & Rungby, J., 2006, I: American Journal of Therapeutics. 13, s. 134-140 7 s.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Hans Henrik Lervang

Fingeraftryk

Publikation

Liraglutide treatment reduced interleukin 6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy

Cardiovascular and other outcomes postintervention with insulin glargine and omega-3 fatty acids (ORIGINALE)

Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention)

Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs

Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs